Harnessing the Immune System to Fight Multiple Myeloma
Multiple myeloma (MM) is a heterogeneous plasma cell malignancy differing substantially in clinical behavior, prognosis, and response to treatment. With the advent of novel therapies, many patients achieve long-lasting remissions, but some experience aggressive and treatment refractory relapses. So...
Main Authors: | Jakub Krejcik, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, Thomas Stauffer Larsen, Torben Barington, Niels Abildgaard |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4546 |
Similar Items
-
Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure
by: Alberto Mussetti, et al.
Published: (2020-10-01) -
Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
by: Ehsan Malek, et al.
Published: (2017-12-01) -
The Role of Immunotherapy in Multiple Myeloma
by: Mehmet Kocoglu, et al.
Published: (2016-01-01) -
Role of Stem Cell Transplantation in Multiple Myeloma
by: Srinivas Devarakonda, et al.
Published: (2021-02-01) -
Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
by: Gösta Gahrton, et al.
Published: (2020-07-01)